Cargando…

Immunotoxicity of silver nanoparticles in an intravenous 28-day repeated-dose toxicity study in rats

BACKGROUND: Nanosilver is used in a variety of medical and consumer products because of its antibacterial activity. This wide application results in an increased human exposure. Knowledge on the systemic toxicity of nanosilver is, however, relatively scarce. In a previous study, the systemic toxicit...

Descripción completa

Detalles Bibliográficos
Autores principales: Vandebriel, Rob J, Tonk, Elisa CM, de la Fonteyne-Blankestijn, Liset J, Gremmer, Eric R, Verharen, Henny W, van der Ven, Leo T, van Loveren, Henk, de Jong, Wim H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052812/
https://www.ncbi.nlm.nih.gov/pubmed/24885556
http://dx.doi.org/10.1186/1743-8977-11-21
_version_ 1782320294674825216
author Vandebriel, Rob J
Tonk, Elisa CM
de la Fonteyne-Blankestijn, Liset J
Gremmer, Eric R
Verharen, Henny W
van der Ven, Leo T
van Loveren, Henk
de Jong, Wim H
author_facet Vandebriel, Rob J
Tonk, Elisa CM
de la Fonteyne-Blankestijn, Liset J
Gremmer, Eric R
Verharen, Henny W
van der Ven, Leo T
van Loveren, Henk
de Jong, Wim H
author_sort Vandebriel, Rob J
collection PubMed
description BACKGROUND: Nanosilver is used in a variety of medical and consumer products because of its antibacterial activity. This wide application results in an increased human exposure. Knowledge on the systemic toxicity of nanosilver is, however, relatively scarce. In a previous study, the systemic toxicity of 20 nm silver nanoparticles (Ag-NP) was studied in a 28-day repeated-dose toxicity study in rats. Ag-NP were intravenously administered with a maximum dose of 6 mg/kg body weight (bw)/day. Several immune parameters were affected: reduced thymus weight, increased spleen weight and spleen cell number, a strongly reduced NK cell activity, and reduced IFN-γ production were observed. METHODS: Prompted by these affected immune parameters, we wished to assess exposure effects on the functional immune system. Therefore, in the present study the T-cell dependent antibody response (TDAR) to keyhole limpet hemocyanin (KLH) was measured in a similar 28-day intravenous repeated-dose toxicity study. In addition, a range of immunological parameters was measured. Data obtained using the benchmark dose (BMD) approach were analyzed by fitting dose-response models to the parameters measured. RESULTS: A reduction in KLH-specific IgG was seen, with a lowest 5% lower confidence bound of the BMD (BMDL) of 0.40 mg/kg bw/day. This suggests that Ag-NP induce suppression of the functional immune system. Other parameters sensitive to Ag-NP exposure were in line with our previous study: a reduced thymus weight with a BMDL of 0.76 mg/kg bw/day, and an increased spleen weight, spleen cell number, and spleen cell subsets, with BMDLs between 0.36 and 1.11 mg/kg bw/day. Because the effects on the spleen are not reflected by increased KLH-specific IgG, they, however, do not suggest immune stimulation. CONCLUSIONS: Intravenous Ag-NP administration in a 28-day repeated-dose toxicity study induces suppression of the functional immune system. This finding underscores the importance to study the TDAR to evaluate immunotoxicity and not to rely solely on measuring immune cell subsets.
format Online
Article
Text
id pubmed-4052812
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40528122014-06-12 Immunotoxicity of silver nanoparticles in an intravenous 28-day repeated-dose toxicity study in rats Vandebriel, Rob J Tonk, Elisa CM de la Fonteyne-Blankestijn, Liset J Gremmer, Eric R Verharen, Henny W van der Ven, Leo T van Loveren, Henk de Jong, Wim H Part Fibre Toxicol Research BACKGROUND: Nanosilver is used in a variety of medical and consumer products because of its antibacterial activity. This wide application results in an increased human exposure. Knowledge on the systemic toxicity of nanosilver is, however, relatively scarce. In a previous study, the systemic toxicity of 20 nm silver nanoparticles (Ag-NP) was studied in a 28-day repeated-dose toxicity study in rats. Ag-NP were intravenously administered with a maximum dose of 6 mg/kg body weight (bw)/day. Several immune parameters were affected: reduced thymus weight, increased spleen weight and spleen cell number, a strongly reduced NK cell activity, and reduced IFN-γ production were observed. METHODS: Prompted by these affected immune parameters, we wished to assess exposure effects on the functional immune system. Therefore, in the present study the T-cell dependent antibody response (TDAR) to keyhole limpet hemocyanin (KLH) was measured in a similar 28-day intravenous repeated-dose toxicity study. In addition, a range of immunological parameters was measured. Data obtained using the benchmark dose (BMD) approach were analyzed by fitting dose-response models to the parameters measured. RESULTS: A reduction in KLH-specific IgG was seen, with a lowest 5% lower confidence bound of the BMD (BMDL) of 0.40 mg/kg bw/day. This suggests that Ag-NP induce suppression of the functional immune system. Other parameters sensitive to Ag-NP exposure were in line with our previous study: a reduced thymus weight with a BMDL of 0.76 mg/kg bw/day, and an increased spleen weight, spleen cell number, and spleen cell subsets, with BMDLs between 0.36 and 1.11 mg/kg bw/day. Because the effects on the spleen are not reflected by increased KLH-specific IgG, they, however, do not suggest immune stimulation. CONCLUSIONS: Intravenous Ag-NP administration in a 28-day repeated-dose toxicity study induces suppression of the functional immune system. This finding underscores the importance to study the TDAR to evaluate immunotoxicity and not to rely solely on measuring immune cell subsets. BioMed Central 2014-05-07 /pmc/articles/PMC4052812/ /pubmed/24885556 http://dx.doi.org/10.1186/1743-8977-11-21 Text en Copyright © 2014 Vandebriel et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Vandebriel, Rob J
Tonk, Elisa CM
de la Fonteyne-Blankestijn, Liset J
Gremmer, Eric R
Verharen, Henny W
van der Ven, Leo T
van Loveren, Henk
de Jong, Wim H
Immunotoxicity of silver nanoparticles in an intravenous 28-day repeated-dose toxicity study in rats
title Immunotoxicity of silver nanoparticles in an intravenous 28-day repeated-dose toxicity study in rats
title_full Immunotoxicity of silver nanoparticles in an intravenous 28-day repeated-dose toxicity study in rats
title_fullStr Immunotoxicity of silver nanoparticles in an intravenous 28-day repeated-dose toxicity study in rats
title_full_unstemmed Immunotoxicity of silver nanoparticles in an intravenous 28-day repeated-dose toxicity study in rats
title_short Immunotoxicity of silver nanoparticles in an intravenous 28-day repeated-dose toxicity study in rats
title_sort immunotoxicity of silver nanoparticles in an intravenous 28-day repeated-dose toxicity study in rats
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052812/
https://www.ncbi.nlm.nih.gov/pubmed/24885556
http://dx.doi.org/10.1186/1743-8977-11-21
work_keys_str_mv AT vandebrielrobj immunotoxicityofsilvernanoparticlesinanintravenous28dayrepeateddosetoxicitystudyinrats
AT tonkelisacm immunotoxicityofsilvernanoparticlesinanintravenous28dayrepeateddosetoxicitystudyinrats
AT delafonteyneblankestijnlisetj immunotoxicityofsilvernanoparticlesinanintravenous28dayrepeateddosetoxicitystudyinrats
AT gremmerericr immunotoxicityofsilvernanoparticlesinanintravenous28dayrepeateddosetoxicitystudyinrats
AT verharenhennyw immunotoxicityofsilvernanoparticlesinanintravenous28dayrepeateddosetoxicitystudyinrats
AT vandervenleot immunotoxicityofsilvernanoparticlesinanintravenous28dayrepeateddosetoxicitystudyinrats
AT vanloverenhenk immunotoxicityofsilvernanoparticlesinanintravenous28dayrepeateddosetoxicitystudyinrats
AT dejongwimh immunotoxicityofsilvernanoparticlesinanintravenous28dayrepeateddosetoxicitystudyinrats